Recent share performance puts Trupanion in focus

Trupanion (TRUP) has drawn investor attention after its share price closed at $24.65, with the stock down about 8% over the past month and about 34% year to date.

Recent moves suggest momentum in Trupanion is fading, with the 7 day share price return down 4.64% and the year to date share price return down 33.74%, alongside a 1 year total shareholder return down 49.31%.

If this kind of reset has you looking beyond pet insurance, it could be a good moment to broaden your search and uncover 19 top founder-led companies

Trupanion’s business keeps bringing in subscription revenue from pet owners, yet the stock has reset sharply over the past year. Do those two realities line up, or is the current share price out of step with the fundamentals?

Most Popular Narrative: 38% Undervalued

The most followed narrative on Trupanion compares a fair value of $39.75 to the recent $24.65 share price, framing the stock as materially discounted and tightly linking that view to specific growth, margin and valuation assumptions.

The moderation in veterinary care inflation, with Trupanion's pricing now catching up and a value proposition restored to target, should lead to more modest premium increases, aiding retention and lowering churn, thereby increasing customer lifetime value and supporting both revenue and earnings stability.

Curious what sits behind that confidence in subscription revenue, margins and a premium valuation multiple that far exceeds typical insurance peers? The narrative leans on detailed assumptions around future earnings power, pricing discipline and how long those economics could hold. The full story connects those moving parts to a single fair value number.

Result: Fair Value of $39.75 (UNDERVALUED)

However, Trupanion’s story could look very different if subscriber growth remains sluggish while acquisition costs stay high, or if competitive pressure forces less favorable pricing.

Another view on Trupanion’s valuation

The fair value narrative points to Trupanion being 38% undervalued at $39.75, yet the current P/E of 41.7x paints a different picture. That compares with 12x for the wider US insurance industry, 7.4x for peers, and a fair ratio estimate of 13.9x.

If the market gradually moves closer to that fair ratio, today’s rich P/E could limit upside and increase the risk of a lower re rating instead. The question for you is whether Trupanion’s subscription model and growth outlook justify staying far above those benchmarks for long.

Next Steps

Given the mix of optimism and concern around Trupanion, it makes sense to look at the numbers yourself and then move quickly to form your own view using 2 key rewards and 1 important warning sign

Looking for more ideas beyond Trupanion?

If Trupanion has sharpened your focus on valuation and risk, now is the moment to widen your watchlist using targeted stock ideas from the Simply Wall St screener.

• Spot potential mispriced opportunities early by scanning screener containing 18 high quality undiscovered gems before other investors catch on.
• Strengthen your core holdings by focusing on companies in the solid balance sheet and fundamentals stocks screener (49 results) that may better handle financial stress.
• Prioritise capital preservation by reviewing 82 resilient stocks with low risk scores so you are not caught off guard by avoidable shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.